Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Reduce” by Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus recommendation of “Reduce” by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $9.6222.

A number of research analysts have weighed in on YMAB shares. Wall Street Zen upgraded Y-mAbs Therapeutics to a “hold” rating in a report on Saturday, September 20th. Cantor Fitzgerald set a $8.60 target price on Y-mAbs Therapeutics and gave the stock a “neutral” rating in a report on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Oppenheimer downgraded Y-mAbs Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 price target on Y-mAbs Therapeutics in a research note on Tuesday, August 5th.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brooklyn Investment Group grew its stake in shares of Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock worth $26,000 after buying an additional 5,796 shares during the last quarter. CWM LLC grew its stake in shares of Y-mAbs Therapeutics by 203.0% in the 2nd quarter. CWM LLC now owns 7,121 shares of the company’s stock worth $32,000 after buying an additional 4,771 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $35,000. Los Angeles Capital Management LLC purchased a new stake in Y-mAbs Therapeutics during the 2nd quarter valued at $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $49,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Price Performance

YMAB opened at $8.61 on Friday. The business has a 50 day simple moving average of $8.48 and a two-hundred day simple moving average of $5.88. The firm has a market capitalization of $391.24 million, a price-to-earnings ratio of -17.22 and a beta of 0.54. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The firm had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. As a group, sell-side analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.